In order to increase public acceptance of an emergency use authorisation for COVID-19 vaccines, the following article in The Lancet suggests that lessons can be learnt from previous experiences with Ebola virus vaccines in Guinea and the Democratic Republic on the Congo.
Emergency use authorisation allows the public to access promising medicinal products prior to licensing and registration. In the setting of a public health emergency, their use may be ethically justified if certain conditions are met.
By having a transparent evaluation process, ensuring that it meets a favourable benefit-risk ratio based on quality and safety data, and having an accountable system of regulatory oversight and monitoring, the ethical quality and overall acceptance of a COVID-19 vaccine can be improved.
To read more follow the link below: